Literature DB >> 15041470

Suppression of receptor-mediated Ca2+ mobilization and functional leukocyte responses by hyperforin.

Christian Feisst1, Oliver Werz.   

Abstract

We have recently identified hyperforin, a lipophilic constituent of the herb Hypericum perforatum (St. John's wort), as a dual inhibitor of the proinflammatory enzymes cyclooxygenase-1 and 5-lipoxygenase. The aim of the present study was to further elucidate antiinflammatory properties and respective targets of hyperforin. We found that hyperforin inhibited the generation of reactive oxygen species (ROS) as well as the release of leukocyte elastase (degranulation) in human isolated polymorphonuclear leukocytes (PMNL), challenged by the G protein-coupled receptor (GPCR) ligand N-formyl-methionyl-leucyl-phenylalanine (fMLP) with an IC 50 approximately equal 0.3 microM. When PMNL were stimulated with phorbol-12-myristate-13-acetate (PMA) or ionomycin, hyperforin (up to 10 microM) failed to inhibit ROS production and elastase release, respectively. Moreover, hyperforin blocked receptor-mediated Ca(2+) mobilization ( IC 50 approximately equal 0.4 and 4 microM, respectively) in PMNL and monocytic cells, and caused a rapid decline of the intracellular Ca(2+) concentration in resting cells. In contrast, the Ca(2+) influx induced by ionomycin or thapsigargin was not suppressed. Comparative studies with the specific phospholipase C inhibitor U-73122 and hyperforin revealed similarities between both compounds. Thus, U-73122 and hyperforin blocked fMLP- and PAF-induced Ca(2+) mobilization, ROS formation, and elastase release, but failed to suppress these responses when cells were stimulated by PMA or ionomycin. Also, both compounds rapidly decreased basal Ca(2+) levels in resting cells and led to a rapid decline of the Ca(2+) elevations evoked by fMLP or PAF. Our data suggest that hyperforin targets component(s) within G protein signaling cascades that regulate Ca(2+) homeostasis, coupled to proinflammatory leukocyte functions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15041470     DOI: 10.1016/j.bcp.2003.12.020

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

1.  Molecular pharmacological profile of a novel thiazolinone-based direct and selective 5-lipoxygenase inhibitor.

Authors:  B Hofmann; C B Rödl; A S Kahnt; T J Maier; A A Michel; M Hoffmann; O Rau; K Awwad; M Pellowska; M Wurglics; M Wacker; A Zivković; I Fleming; M Schubert-Zsilavecz; H Stark; G Schneider; D Steinhilber
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  Hypericum perforatum modulates apoptosis and calcium mobilization through voltage-gated and TRPM2 calcium channels in neutrophil of patients with Behcet's disease.

Authors:  Mustafa Nazıroğlu; Mehmet Sahin; Bilal Ciğ; Mehmet Aykur; Ijlal Erturan; Yunus Ugan
Journal:  J Membr Biol       Date:  2014-01-23       Impact factor: 1.843

3.  Hyperforin is a novel type of 5-lipoxygenase inhibitor with high efficacy in vivo.

Authors:  Christian Feisst; Carlo Pergola; Marija Rakonjac; Antonietta Rossi; Andreas Koeberle; Gabriele Dodt; Marika Hoffmann; Christina Hoernig; Lutz Fischer; Dieter Steinhilber; Lutz Franke; Gisbert Schneider; Olof Rådmark; Lidia Sautebin; Oliver Werz
Journal:  Cell Mol Life Sci       Date:  2009-07-05       Impact factor: 9.261

4.  Hyperforin, an Anti-Inflammatory Constituent from St. John's Wort, Inhibits Microsomal Prostaglandin E(2) Synthase-1 and Suppresses Prostaglandin E(2) Formation in vivo.

Authors:  Andreas Koeberle; Antonietta Rossi; Julia Bauer; Friederike Dehm; Luisella Verotta; Hinnak Northoff; Lidia Sautebin; Oliver Werz
Journal:  Front Pharmacol       Date:  2011-02-18       Impact factor: 5.810

5.  Population Variability of Main Secondary Metabolites in Hypericum lydium Boiss. (Hypericaceae).

Authors:  Cüneyt Çirak; Jolita Radusiene; Liudas Ivanauskas; Valdas Jakstas; Necdet Çamaş
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

6.  Targeting the pregnane X receptor using microbial metabolite mimicry.

Authors:  Zdeněk Dvořák; Felix Kopp; Hao Li; Aneta Vrzalová; Cait M Costello; Jazmin S Kemp; Martina Štěpánková; Iveta Bartoňková; Eva Jiskrová; Karolína Poulíková; Barbora Vyhlídalová; Lars U Nordstroem; Chamini V Karunaratne; Harmit S Ranhotra; Kyu Shik Mun; Anjaparavanda P Naren; Iain A Murray; Gary H Perdew; Julius Brtko; Lucia Toporova; Arne Schön; Bret D Wallace; William G Walton; Matthew R Redinbo; Katherine Sun; Amanda Beck; Sandhya Kortagere; Michelle C Neary; Aneesh Chandran; Saraswathi Vishveshwara; Maria M Cavalluzzi; Giovanni Lentini; Julia Yue Cui; Haiwei Gu; John C March; Shirshendu Chatterjee; Adam Matson; Dennis Wright; Kyle L Flannigan; Simon A Hirota; Ryan Balfour Sartor; Sridhar Mani
Journal:  EMBO Mol Med       Date:  2020-03-10       Impact factor: 12.137

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.